10-Q: Myriad Genetics Q3 Loss Widens Amid Impairments, New Debt

Myriad Genetics reported a wider net loss in the third quarter and first nine months of 2025, driven by significant goodwill and intangible asset impairment charges, despite some revenue growth in Hereditary Cancer and Prenatal segments.

Summary

• Net loss for the three months ended September 30, 2025, was $27.4 million, compared to $22.1 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $358.0 million, a significant increase from $84.8 million in the prior year.
• Total revenue decreased by $7.6 million to $205.7 million for the three months ended September 30, 2025, and by $12.3 million to $614.7 million for the nine months ended September 30, 2025, compared to the respective prior periods.
• Goodwill and long-lived asset impairment charges totaled $316.7 million for the nine months ended September 30, 2025, including $234.7 million for goodwill and $82.0 million for intangible assets.
• Pharmacogenomics revenue decreased by $9.0 million for the three months and $22.1 million for the nine months ended September 30, 2025, primarily due to a 25% and 21% decrease in average revenue per test, respectively, impacted by UnitedHealthcare's coverage changes for GeneSight.
• Hereditary Cancer revenue increased by $2.5 million (3%) for the three months and $5.5 million (2%) for the nine months ended September 30, 2025, driven by volume growth.
• Prenatal revenue increased by $1.0 million (2%) for the three months and $9.2 million (7%) for the nine months ended September 30, 2025, due to an 11% increase in average revenue per test for the nine-month period.
• The company secured a new $200.0 million term loan credit facility on July 31, 2025, with an initial $125.0 million funded, and repaid its previous $60.2 million asset-based revolving credit facility.
• Cash and cash equivalents increased by $43.0 million to $145.4 million as of September 30, 2025, compared to December 31, 2024, largely due to proceeds from the new credit facility.
• Benjamin R. Wheeler was appointed Chief Financial Officer effective August 16, 2025, as part of recent senior management changes.

Sentiment

Score: 3

Explanation: The company reported a substantial net loss driven by significant impairment charges, and faces ongoing revenue challenges in its Pharmacogenomics segment due to payor coverage changes, despite some positive strategic developments and cash flow improvements from financing.

Positives

• Hereditary Cancer revenue increased by $2.5 million (3%) for the three months and $5.5 million (2%) for the nine months ended September 30, 2025, driven by volume growth.
• Prenatal revenue increased by $1.0 million (2%) for the three months and $9.2 million (7%) for the nine months ended September 30, 2025, with an 11% increase in average revenue per test for the nine-month period.
• Net cash used in operating activities improved by $6.5 million, decreasing to $8.8 million for the nine months ended September 30, 2025, compared to $15.3 million in the prior year.
• The company secured a new $200.0 million term loan credit facility, providing $125.0 million in initial funding and access to an additional $75.0 million, enhancing liquidity.
• A new meta-analysis published in September 2025 showed that the GeneSight Psychotropic test significantly improved response and remission rates for patients with major depressive disorder.
• The company announced a strategic collaboration with SOPHiA Genetics, Inc. in September 2025 to develop a global liquid biopsy companion diagnostic (CDx) test.
• The U.S. District Court for the Eastern District of Texas vacated the FDA's final rule to regulate laboratory developed tests (LDTs), preserving the existing enforcement-discretion policy and reducing immediate regulatory burden.

Negatives

• Net loss significantly widened to $358.0 million for the nine months ended September 30, 2025, compared to $84.8 million in the prior year.
• Goodwill and long-lived asset impairment charges totaled $316.7 million for the nine months ended September 30, 2025, a substantial increase from $13.8 million in the prior year.
• Total revenue decreased by $7.6 million for the three months and $12.3 million for the nine months ended September 30, 2025.
• Pharmacogenomics revenue decreased by $9.0 million (19%) for the three months and $22.1 million (17%) for the nine months ended September 30, 2025, primarily due to a 25% and 21% decrease in average revenue per test, respectively.
• UnitedHealthcare's change in GeneSight test coverage under its commercial, individual exchange, and certain managed Medicaid benefit plans continues to negatively affect Pharmacogenomics revenue, profitability, and cash flow.
• Interest expense increased significantly to $3.8 million for the three months and $6.1 million for the nine months ended September 30, 2025, due to the new term loan.
• Total assets decreased by $299.5 million to $728.1 million as of September 30, 2025, from $1,027.6 million at December 31, 2024, largely due to impairment charges.
• Total stockholders' equity decreased by $328.3 million to $372.8 million as of September 30, 2025, from $701.1 million at December 31, 2024.

Risks

• Sales and profit margins of existing tests may decline.
• The company may not be able to operate its business on a profitable basis.
• Inability to achieve certain revenue growth targets and generate sufficient revenue from existing or new products.
• Risks related to recent changes in the senior management team and the successful implementation of the company's strategic plan.
• Changes in governmental or private insurers' coverage and reimbursement levels for tests, including UnitedHealthcare's coverage decisions for GeneSight.
• Increased competition and the development of new competing tests.
• Inability to develop or achieve commercial success for additional tests in a timely manner.
• Inability to secure additional financing on favorable terms, if needed.
• Termination or inability to maintain licenses to the technology underlying tests.
• Delays or other problems with operating laboratory testing facilities.
• Public concern over genetic testing in general or specific tests.
• Regulatory requirements or enforcement in the United States and foreign countries and changes in healthcare systems.
• Inability to obtain new corporate collaborations or licenses and acquire or develop new technologies or businesses.
• Inability to successfully integrate and derive benefits from licensed, acquired, or developed technologies or businesses.
• Risks related to projections or estimates about the potential market opportunity for current and future products.
• Inability to protect proprietary technologies or infringement by third parties.
• Patent-infringement claims or challenges to patent validity.
• Changes in intellectual property laws covering tests or patents.
• Security breaches, loss of data, and other disruptions, including cyberattacks.
• Inability to keep pace with rapid technology changes in the industry.
• Inability to comply with financial or operating covenants under credit or lending agreements.
• Inability to maintain effective disclosure controls and procedures and internal control over financial reporting.
• Risks related to current and future investigations, claims, or lawsuits, including derivative claims and product/professional liability claims.
• Impact of inflation on labor costs, sales generation, testing results production, and laboratory supplies.

Future Outlook

The company's strategy is focused on three pillars: driving accelerated growth and profitability in the Cancer Care Continuum (CCC) market, growing Prenatal Health and Mental Health revenues at or above market growth, and delivering sustained, profitable growth through financial discipline. The negative impact of UnitedHealthcare's coverage decision on Pharmacogenomics revenue is expected to continue in future periods. The company believes its existing capital resources will be sufficient to meet projected operating requirements for at least the next 12 months, but acknowledges risks if cash is consumed more rapidly or additional funding is not secured.

Management Comments

• "We remain committed to disciplined cost management while maintaining investments in key strategic areas, such as research and development."
• "We believe there are significant growth opportunities in addressing urgent healthcare needs through innovative molecular diagnostic and precision testing services."

Industry Context

The molecular diagnostic and precision medicine industry continues to face a complex landscape characterized by rapid technological advancements, evolving regulatory oversight, and persistent reimbursement challenges. Myriad Genetics' strategic focus on the Cancer Care Continuum and expanded prenatal offerings aligns with key growth segments in the diagnostics market. However, the significant impairment charges and revenue decline in Pharmacogenomics, largely due to payor policy changes like UnitedHealthcare's, highlight a broader industry trend where diagnostic companies must continually demonstrate clinical utility and cost-effectiveness to secure and maintain coverage. The vacatur of the FDA's LDT final rule provides temporary relief from immediate regulatory burdens but underscores ongoing uncertainty regarding future federal oversight of laboratory-developed tests.

Comparison to Industry Standards

• The positive meta-analysis results for the GeneSight Psychotropic test, showing significant improvements in response and remission rates for MDD patients compared to 'treatment as usual,' provide strong clinical validation, positioning it favorably against other pharmacogenomic tests or standard care approaches in mental health.
• The strategic collaboration with SOPHiA Genetics, Inc. to develop a global liquid biopsy companion diagnostic (CDx) test places Myriad in a competitive, high-growth segment of precision oncology, aligning with industry leaders like Guardant Health and Foundation Medicine who are advancing liquid biopsy technologies.
• Myriad's strategic pillars, particularly the focus on the Cancer Care Continuum (CCC) and molecular residual disease (MRD), reflect an industry-wide trend towards comprehensive cancer care and early detection, mirroring strategies of companies such as Natera (Signatera for MRD) and Exact Sciences (Oncotype DX).
• The challenges faced with UnitedHealthcare's coverage for multi-gene panel pharmacogenetic tests, including GeneSight, are indicative of a broader industry hurdle where payors increasingly scrutinize the clinical utility and cost-effectiveness of advanced diagnostic tests, impacting numerous diagnostic companies seeking reimbursement.

Management Changes

Corporate Governance

Legal Proceedings

• A qui tam complaint, filed on November 3, 2022, was unsealed on January 22, 2025, and served on the company on April 16, 2025. It alleges violations of the False Claims Act against the company and certain former employees concerning remuneration to physicians at Carolina Urology Partners, PLLC. The government declined to intervene, and the company filed a motion to dismiss the complaint in June 2025.

Stakeholder Impact

• Shareholders: Experienced a significant decrease in total stockholders' equity due to the substantial net loss and impairment charges. Potential for future share price volatility due to financial performance, regulatory uncertainty, and ongoing litigation. The equity incentive plan amendment could lead to dilution.
• Employees: Significant changes in the senior management team, including a new CFO and other key executive appointments. The company's growth and commercial expansion place additional demands on the workforce.
• Customers (Healthcare Providers/Patients): Benefit from continued availability of molecular diagnostic tests, new gene additions to the Foresight Carrier Screen, and a strategic collaboration for a liquid biopsy CDx test. Positive clinical outcomes for the GeneSight test were published.
• Payors (e.g., UnitedHealthcare): Ongoing challenges with coverage and reimbursement for certain multi-gene panel pharmacogenetic tests, including GeneSight, continue to negatively impact the company's revenue.
• Creditors: The company secured a new $200.0 million term loan credit facility, with $125.0 million funded, and repaid its previous ABL facility. The company was in compliance with all covenants under the new Credit Agreement as of September 30, 2025.

Next Steps

• Continue to monitor for additional indicators of impairment in future periods.
• Continue to monitor developments and assess future implications of the One Big Beautiful Bill Act as further guidance becomes available.
• The West Salt Lake City facility lease amendment for additional laboratory space is expected to commence in 2026.
• Management will continue to defend the qui tam lawsuit.
• The FDA could seek to reissue a revised rule or the U.S. Congress could enact new legislation regarding laboratory developed tests (LDTs).
• Scheduled principal payments on the Credit Facility commence on September 30, 2029.
• Delayed Draw Loans are available until June 30, 2027.

Key Dates

Recommendation

Myriad Genetics reported a substantial net loss driven by significant impairment charges and faces ongoing revenue pressure in its Pharmacogenomics segment due to payor coverage changes. While the company is actively pursuing strategic growth initiatives in Cancer Care Continuum and Prenatal Health, has secured new financing, and published positive clinical data for GeneSight, the current financial performance and market uncertainties warrant a cautious approach. A 'Hold' recommendation suggests monitoring the execution of the strategic plan, reimbursement trends, and the outcome of legal/regulatory matters before making further investment decisions.

Keywords

Myriad Genetics, MYGN, molecular diagnostics, genetic testing, precision medicine, hereditary cancer, tumor profiling, prenatal testing, pharmacogenomics, GeneSight, SEC filing, 10-Q, financial results, impairment charges, debt facility, healthcare, biotechnology, corporate governance